September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Efficacy and Safty of Simultaneous Dexamethasone Intravitreal Implant and Bevacizumab Compared with Bevacizumab Monotherapy for Branched Retinal Vein Occlusion
Author Affiliations & Notes
  • Kui Dong Kang
    Ophthalmology, Catholic Univ of Korea, Incheon,
  • Yun Junmyeong
    Ophthalmology, Catholic Univ of Korea, Incheon,
  • Hyungbin Hwang
    Ophthalmology, Catholic Univ of Korea, Incheon,
  • Su Ah Kim
    Department of Ophthalmology, SahmYook Medical Center, Seoul, Korea (the Republic of)
  • Kyung-A Kim
    KIST, Gangneung, Korea (the Republic of)
  • Tae-Jin Kim
    KIST, Gangneung, Korea (the Republic of)
  • Man Jae Kwon
    KIST, Gangneung, Korea (the Republic of)
  • Sang Hoon Jung
    KIST, Gangneung, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Kui Dong Kang, None; Yun Junmyeong, None; Hyungbin Hwang, None; Su Ah Kim, None; Kyung-A Kim, None; Tae-Jin Kim, None; Man Jae Kwon, None; Sang Hoon Jung, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5331. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kui Dong Kang, Yun Junmyeong, Hyungbin Hwang, Su Ah Kim, Kyung-A Kim, Tae-Jin Kim, Man Jae Kwon, Sang Hoon Jung; Efficacy and Safty of Simultaneous Dexamethasone Intravitreal Implant and Bevacizumab Compared with Bevacizumab Monotherapy for Branched Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5331.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study was performed to determine whether a simultaneous injection of dexamethasone intravitreal implant 0.7 mg (dexamethasone delivery system [DDS], OzurdexTM) and bevacizumab 1.25 mg is more effective than bevacizumab monotherapy for the treatment of branched retinal vein occlusion (BRVO).

Methods : Treatment and outcomes data were collected retrospectively for 51 eyes from 51 patients who underwent simultaneous DDS and bevacizumab injection or bevacizumab injection alone. The treatment protocol was to inject DDS and bevacizumab simultaneously at baseline, and subsequent bevacizumab (at Months 1 and 2) in the combined treatment group (n=24), whereas monotherapy eyes (n=27) received bevacizumab monthly for 3 months (including baseline). Outcome measures included visual acuity, central retinal thickness (CMT) at 3 and 6 month after initial treatment, and pain questionnaire scores were calculated at the day of injection.

Results : The mean visual acuity changes from baseline to 6 months were similar in the 2 groups (combined: +7.4 letters; bevacizumab: +6.9 letters; P=0.32), however at 3 months, there was a significant improvement in mean visual acuity (+8.1 lines, P< 0.05) in eyes with simultaneous DDS and bevacizumab injection compared to bevacizumab alone. The mean reduction in CMT was greater in the combination group at both 3 and 6 month (P< 0.05). The pain questionnaire score was greater in the combined group (P<0.05) and no adverse effect was observed in both groups.

Conclusions : Simultaneous injection of dexamethasone implant combined with bevacizumab significantly improves visual acuity in a relatively short period compared to bevacizumab alone and improves macular morphology in eyes with BRVO.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×